Background Various genome-wide association studies (GWAS) have been done in ischaemic stroke, identifying a few loci associated with the disease, but sample sizes have been 3500 cases or less. We established the METASTROKE collaboration with the aim of validating associations from previous GWAS and identifying novel genetic associations through meta-analysis of GWAS datasets for ischaemic stroke and its subtypes.
Introduction
Stroke is one of the three most common causes of death, is a major cause of adult chronic disability, 1 and represents an important cause of age-related cognitive decline and dementia. Conventional risk factors explain only a small proportion of all stroke risk. 2 Evidence from studies of twins and family history suggests that genetic predisposition is important. 3 In common with many other complex diseases, in which environmental risk factors are thought to interact with multiple genes, the identifi cation of the underlying molecular mechanisms contributing to stroke risk has been a challenge. Can didate gene studies have produced few replicable associations. 4 More recently, the genome-wide asso ciation study (GWAS) approach has transformed the genetics of other complex diseases and is just beginning to aff ect the study of stroke. 5, 6 About 80% of stroke is ischaemic, whereas 20% is due to primary haemorrhage. 6 Ischaemic stroke itself includes several subtypes with diff ering pathophysiological mechanisms, the most common of which are large-vessel disease stroke, small-vessel disease stroke, and cardioembolic stroke. 7 Various genetic variants that predispose to risk factors for stroke have also been shown in GWAS to predispose to ischaemic stroke. [8] [9] [10] Two loci associated with atrial fi brillation (PITX2 and ZFHX3) were associated with cardioembolic stroke, whereas a locus on chromosome 9p21 originally associated with coronary artery disease was shown to be a risk factor for large-vessel stroke. [8] [9] [10] The few novel stroke-associated loci reported to date have been mainly associated with stroke subtypes, rather than with the phenotype of ischaemic stroke. In Japanese populations, a variant in the protein kinase C family (PRKCH) was associated with small-vessel stroke. 11 A meta-analysis of prospective populationbased cohort studies reported an association with the 12p13 region, thought to be with the NINJ2 gene, although this result was not replicated in a larger casecontrol sample. 12, 13 Recently, the Wellcome Trust Case Control Consortium 2 (WTCCC2) GWAS in ischaemic stroke reported a novel association on chromosome 7p21 within the HDAC9 gene, although it was associated only with large-vessel ischaemic stroke. 14 GWAS in ischaemic stroke to date have used small discovery populations, with the largest including 3548 individuals. 14 In other complex diseases, many add itional associations have been detected as the discovery sample size has increased. [15] [16] [17] This increase has usually been achieved by meta-analysis of independent datasets. Therefore, we established the METASTROKE collab oration to combine the available GWAS datasets of ischaemic stroke. Here, we describe the fi rst paper from METASTROKE with a description of the constituent cohorts. Using this dataset, we attempted both to replicate previous GWAS associations with ischaemic stroke and to identify novel associations. Additionally, we determined whether stroke loci were specifi c to individual stroke subtypes.
Methods

Study design and participating studies
The discovery sample consisted of 15 cohorts of patients with ischaemic stroke who were of European ancestry from Europe, North America, and Australia, together with controls of matched ancestry. All studies used a case-control methodology. Most participating studies were cross-sectional, whereas four were in large, prospective, population-based cohorts (table 1) .
Additionally, 18 cohorts were analysed in the replication phase. These cohorts were included for replication only, most did not have GWAS data available; and those with GWAS data were not available at the time of the discovery analysis. 17 of the included cohorts contained individuals of solely European ancestry, and one contained individuals of Pakistani ancestry (table 1). Most cohorts (16) were cross-sectional, whereas two were population-based.
The appendix includes detailed descriptions of the design and clinical characteristics of the participating studies.
Stroke was defi ned as a typical clinical syndrome with radiological confi rmation. Stroke subtyping was done with the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classifi cation system. 18 Where subtyping was done, brain CT or MRI was undertaken for more than 95% of cases in all the discovery cohorts.
Participating studies were approved by relevant institutional review boards, and all participants gave written or oral consent for study participation, including genetic research, as approved by the local institutional body.
Data imputation and statistical analysis
The 15 discovery cohorts used commercially available GWAS panels of single nucleotide polymorphisms (SNPs) from either Aff ymetrix (Santa Clara, CA, USA) or Illumina (San Diego, CA, USA). 14 of the 15 centres undertook genotype imputation with HapMap II, 19 HapMap III, 20 or 1000 Genomes 21 as reference haplotype training sets. Every centre did genotypic quality control steps before imputation, including removal of ancestry outliers defi ned by principal component analysis and poorly typed individuals.
We used logistic regression for all cohorts with a crosssectional study design to model the multiplicative SNP eff ects on risk for the dichotomous outcome of stroke against ancestry-matched controls, whereas we used Cox proportional-hazards models for the prospective studies to assess time to fi rst stroke, fi tting an additive model relating genotype dose to the stroke outcome. Where genotypes were imputed, SNPs were modelled as allele dosages. Of the discovery cohorts, four (of 15) centres used ancestry-informative principal components as covariates to correct for population stratifi cation. All cohorts providing genome-wide data removed population outliers before imputation. After verifying strand alignment, fi ltering SNPs with minor allele frequency lower than 0·01, and removing poorly imputed SNPs across centres, we did a meta-analysis of the results of the association analyses from every centre using a fi xedeff ects inverse-variance weighted model using METAL. 22 We sought further evidence for association with novel suggestively associated SNPs in new samples from 18 diff erent cohorts. Of the 18 centres, six submitted insilico genotype data and 12 undertook direct genotyping with the Sequenom (Sequenom, San Diego, CA, USA) or Taqman (Applied Biosystems, Foster City, CA, USA) platforms. All of the fi ve replication cohorts contributing genome-wide data used principal components as covariates in their analyses. We did a meta-analysis of the results for the replication cohorts using a fi xed-eff ects, inverse variance weighted method fi rst for all datasets, and then for replication datasets of solely European ancestry. We determined whether SNPs were signifi cantly associated in the replication population, and additionally, we combined results from the discovery and replication analyses using a fi xed-eff ects, inverse-variance weighted approach.
See Online for appendix
We set the study-wide genome-wide signifi cance level at p<5×10 -⁸ to control the experiment-wide error rate to <5%. Following the example of previous GWAS studies, 15 we set the level for suggestive signifi cance at p<5×10 -⁶.
First, we attempted to determine the evidence for association for the six loci reported previously from GWAS to be associated with ischaemic stroke (HDAC9, PITX2, ZFHX3, NINJ2, PRKCH, and 9p21). [8] [9] [10] [11] [12] 14 After determining the evidence for association with the previously reported SNPs, we investigated whether any proxy SNPs were more signifi cantly associated in the METASTROKE dataset. Because some loci had been identifi ed in discovery populations included in METASTROKE, we initially did analyses for the whole dataset, and then we restricted analysis to the lead SNP for every locus in the METASTROKE cohorts that had not been included in the discovery phase of the initial publication. We set the signifi cance level for independent replication at p<0·01, corresponding to Bonferroni corrected type 1 error <5% for the fi ve SNPs (excluding PRKCH) tested. As the SNP in PRKCH (rs2230500) underlying the previous association in Japanese cohorts 1 is mono morphic in populations of European ancestry, we sought to identify any associations within this gene region, including the 50 kbp window upstream and downstream, in our large population of European ancestry. Using the modifi ed Nyholt correction approach of Li and Ji on the 353 SNPs from the region, we estimated the eff ective number of SNPs tested to be 103·3. 23 We therefore set the signifi cance level at p<0·00048, corresponding to Bonferroni corrected type I error <5% for the eff ective SNPs tested.
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We also did an analysis to determine whether the six previously reported variants were associated with stroke risk in prospective population-based studies. We did this analysis only for the known SNPs that had been analysed in a minimum of 100 cases in the prospective cohorts with incident stroke events for the relevant subtype.
For those associations we could confi rm, we then did a conditional analysis within the associated region to identify any signal in the region that was independent of the lead SNP in every case. For every association, we selected regions used in the conditional analysis on the basis of adjacent recombination hotspots, meaning we analysed diff erent numbers of SNPs for every locus (appendix). We used logistic regression in every centre, using imputed genotype dosages to model the eff ect of the lead SNP on risk as a covariate. We then did a meta-analysis of the results using a fi xed-eff ects, inverse-variance weighted model. We used our suggestive signifi cance threshold (p<5×10 -⁶) to identify SNPs that were statistically independent of the lead SNP for every locus.
We then did a meta-analysis of the genome-wide studyspecifi c analysed datasets to identify novel associations with ischaemic stroke and its subtypes. We did the primary association analyses for all ischaemic stroke and for the three major subtypes: cardioembolic stroke, largevessel disease, and small-vessel disease. We did additional secondary analyses for young cases (younger than 70 years at fi rst stroke) and for the phenotype of ischaemic stroke in each sex separately. We reused the same controls per centre for all analyses. Excluding the previously published associations, we considered all SNPs reaching suggestive signifi cance (p<5×10 -⁶) for replication. We examined SNPs for heterogeneity across datasets and attempted replication in independent datasets for the loci that were deemed plausible candidates for association with ischaemic stroke.
For a minor allele frequency of 0·25, we had 80% power to detect variants with a per-allele odds ratio (OR) greater than 1·11 for the all ischaemic stroke analysis, 1·23 for cardioembolic stroke, 1·24 for large-vessel disease, and 1·26 for small-vessel disease at p<5×10 -⁸ in the discovery phase.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The discovery meta-analysis of ischaemic stroke phenotypes involved a total of 12 389 cases and 62 004 controls from 15 populations (table 1; fi gure 1).
The discovery meta-analysis confi rmed associations at genome-wide signifi cance levels for HDAC9 with largevessel disease, and for both PITX2 and ZFHX3 with cardioembolic stroke (table 2) . For PITX2, ZFHX3, and HDAC9 a proxy SNP was more signifi cant in the METASTROKE dataset than the SNP from the original publication (original SNP shown in appendix). The 9p21 locus was associated with large-vessel disease with a similar OR (1·15, 95% CI 1·08-1·23, in METASTROKE) to that reported previously (1·21, 1·07-1·37), 10 although it did not reach genome-wide signifi cance (p=3·32×10 -⁵). All four associations were subtype specifi c, being present only for a single stroke subtype (table 2) . To determine the extent to which these results replicated the fi ndings from the originally published associations, we repeated the meta-analysis, this time excluding the populations that contributed to the discovery phase of the original publication. For the PITX2, ZFHX3, HDAC9, and 9p21 loci, the associations were replicated in the independent METASTROKE samples (table 2). The population attributable risks in the METASTROKE discovery cohort were estimated as 5·8% for PITX2 and 7·0% for ZFHX3 in cardioembolic stroke, and 4·5% for HDAC9 and 7·2% for 9p21 in largevessel disease.
The NINJ2 locus showed nominal evidence of association with all ischaemic stroke when all populations were included (table 2) . However, no evidence was noted for association with the NINJ2 locus when the original discovery populations were excluded (table 2) .
To estimate the eff ect of these associations in prospective population-based studies, we had a suffi cient number of stroke cases for the analysis in only the cardioembolic subtype (n=376). We noted ORs similar to those identifi ed in the overall case-control study for both PITX2 (1·26, 95% CI 1·05-1·52, in prospective studies and 1·36, 1·27-1·47, in case-control analysis) and ZFHX3 (1·23, 0·98-1·55, in prospective studies and 1·25, 1·15-1·35, in case-control analysis), although this similarity was signifi cant only for PITX2 (appendix).
We found no signifi cant associations between the PRKCH gene region and all ischaemic strokes or with the three main subtype analyses. Table 2 provides details of the most strongly associated SNPs in every subtype for this locus.
For those loci for which we confi rmed genome-wide signifi cance (PITX2, ZFHX3, and HDAC9), we did conditional analyses. After conditioning on the lead SNP in the given region, no SNP showed signifi cance at p<0·01 in PITX2 or ZFHX3, and no SNP showed signifi cance at p<0·005 in HDAC9. Furthermore, all other SNPs in the regions that were associated at p<5×10 -⁸ in the main analysis showed no signifi cance (p>0·05) in any of the analyses after conditioning on the lead SNP. Figure 2 shows plots of -log 10 (p values) against genomic position in the selected regions for the unconditional and conditional analyses.
We selected a total of 12 novel SNPs for testing in the independent replication cohort: three associated with all ischaemic stroke, fi ve associated with specifi c stroke subtypes, and two each associated with young stroke and female stroke. Four of these SNPs showed associations close to genome-wide signifi cance in the discovery cohort: rs225132 in the ERRF11 gene and rs17696736 in the NAA25 (C12orf30) gene with all ischaemic stroke (p=6·3×10 -⁸ and 5·9×10 -⁸, respectively), rs7937106 in ALKBH8 with large-vessel disease (p=5·9×10 -⁸), and rs13407662 on chromosome 2p16.2 (p=5·2×10 -⁸) in an intergenic region with small-vessel disease. The remaining SNPs were identifi ed at the suggestive signifi cance level of p<5×10 -⁶. Table 3 shows details of these SNPs, including stroke subtypes with which they were associated, and signifi cance levels. These 12 novel SNPs were taken forward for replication in an additional 13 347 cases and 29 083 controls. Figure 3 shows the plots of -log 10 (p values) by chromosomal location for the analysis of all stroke and the three main subtypes. None of the novel SNPs reached genome-wide signifi cance on combination of the discovery and replication data. This result was the same when replication analysis was restricted to individuals of European ancestry (table 3) . There was signifi cant heterogeneity (p<0·05) for all of the SNPs in the combined analysis. We had suffi cient sample size to obtain 80% power to confi rm each of the 12 loci (appendix).
Discussion
METASTROKE is the fi rst large meta-analysis of stroke GWAS data (panel). The METASTROKE collaboration brings together GWAS data from more than 12 000 cases of ischaemic stroke and 60 000 controls from 15 cohorts all of European ancestry. In this fi rst analysis from the dataset, we confi rmed four of fi ve previously described associations with ischaemic stroke in populations of European ancestry, including replication in an independent non-overlapping sample of the dataset not included in the original GWAS. All these associations were with specifi c subtypes of ischaemic stroke, emphasising the genetic heterogeneity of the disease. Additionally, we identifi ed several promising novel associations, some of which were close to genome-wide signifi cance in the discovery cohorts, but these were not confi rmed in our replication population.
Our results provide further robust data supporting an association between two gene regions (PITX2 and ZFHX3) and cardioembolic stroke, and a further two (HDAC9 and 9p21) with large-vessel stroke although the 9p21 locus did not reach genome-wide signifi cance. In all cases, these associations were present in the dataset as a whole, and also when those samples used in the original discovery cohorts that identifi ed associations with ischaemic stroke were excluded.
Both PITX2 and ZFHX3 were originally identifi ed as risk factors for atrial fi brillation. 8, 9 Atrial fi brillation is a major risk factor for stroke, particularly in the elderly, and therefore their association with ischaemic stroke is not unexpected. Our results confi rm this association and clearly show that it is limited to the cardioembolic stroke subtype. Furthermore, we were able to show an association between PITX2 and ischaemic stroke in prospective cohorts. A potential bias is that a variant that is in fact associated with mortality rate after acute stroke and not with stroke risk might seem to be related to risk; for cross-sectional studies in a disease such as stroke, which has substantial early mortality, death might occur before or soon after hospital admission before samples are taken. In a prospective study, such cases are included All ischaemic stroke
Large-vessel disease
Cardioembolic stroke
Small-vessel disease
as the sample was taken at recruitment to the study and therefore before the onset of stroke. By contrast, the HDAC9 and 9p21 associations were specifi c to large-vessel stroke, and not present with other stroke subtypes. An association with the 9p21 locus was fi rst associated with myocardial infarction and coronary artery disease but has now been associated more widely with other arterial diseases such as aneurysms and ischaemic stroke. 10, 24 HDAC9 was recently identifi ed in the WTCCC2 ischaemic stroke study as a novel association with ischaemic stroke, 14 having not previously been shown in GWAS analyses of ischaemic heart disease.
For the PITX2, ZFHX3, and HDAC9 associations, we did a conditional analysis to establish whether the lead SNP that we had identifi ed was suffi cient to model all of the associations within that region, or whether other independent genetic variants were associated with disease. In every case, no signifi cant association remained after controlling for the lead SNP, suggesting that all the signal in each region can be attributed to one risk haplotype.
A meta-analysis of prospective cohort studies reported an association between ischaemic stroke and a SNP in the 12p13 region, although this was not replicated in an independent study. 13 The underlying gene was suggested to be NINJ2. 12 This association was present in the METASTROKE discovery cohort, but this cohort contained the datasets in which the original association had been determined. When these datasets were excluded, there was no evidence of any associations.
In a Japanese population, a variant in PRKCH has been associated with small-artery disease, a stroke sub type that is particularly common in this ethnic group. 11 This association was confi rmed in a prospective study with relatively few stroke endpoints, and also in a Chinese population. 25, 26 Interestingly, an association was also suggested with cerebral haemorrhage, which shares some underlying pathological similarities with cerebral small-vessel disease causing lacunar infarction. The association has not yet been examined in other ancestral groups. The SNP is monomorphic in European populations and therefore we were unable to examine whether the association was present in our population. However, we assessed all SNPs at this chromosomal region and noted no evidence of any association in our population of European ancestry.
We identifi ed associations at four loci that were near genome-wide signifi cance in the discovery cohort and had not been associated with stroke in previous studies: SNPs in the ERRF11 and NAA25 (C12orf30) genes with all ischaemic stroke, a SNP in ALKBH8 with large-vessel stroke, and rs13407662 on chromosome 2p16.2 in an intergenic region with small-vessel disease. We took these four forward, with an additional eight of the strongest associations that had not reached genome-wide signifi cance, to replication in an independent sample. None of the associations replicated. Our replication sample contained a cohort of patients of Pakistani ancestry, but, restriction of our analysis to individuals of European ancestry did not alter the results.
The same risk allele of SNP rs17696736 in the NAA25 gene has previously been associated with type 1 diabetes in a large genome-wide association study. 27 Other SNPs in this 12q24 region have also been implicated in several of related phenotypes including microcirculation in vivo, platelet count, and blood pressure. [28] [29] [30] None of the other three associations near to genome-wide signifi cance have previously been associated with cardio vascular or neurological disease. 
Chr=chromosome. SNP=single nucleotide polymorphism. RA=risk allele. RAF=risk allele frequency. p discovery =one-sided p value in discovery cohorts. OR discovery =odds ratio in discovery cohorts. p replication ,=one-sided p value in replication cohorts. OR replication =odds ratio in replication cohorts. p combined =one-sided p value in all cohorts combined. IS=all ischaemic stroke. CS=cardioembolic stroke. LVD=large-vessel disease. SVD=smallvessel disease. FS=female-only stroke. YS=young stroke.
Table 3: Association signals for SNPs selecting for testing in the independent replication cohort by subtype
Our inability to replicate any of the novel associations we identifi ed in the discovery phase could be explained by various factors. All non-imputed SNPs in all cohorts were checked for Hardy-Weinberg equilibrium and standard quality control measures were done, including checking for sex mismatch on the basis of three genotypic markers, but we cannot rule out confounding by other means. For example, many of the 12 replication cohorts only directly genotyped the 12 replication SNPs. First, this type of analysis provides no means of adjustment for ancestry-informative principal components, which could lead to results being adversely aff ected by popu lation structure. Second, our strategy of attempting replication with one SNP from each region might not have been optimum. In regions such as the 12q24 locus, where the linkage disequilibrium patterns are complex, attempting replication in multiple SNPs might have proved more fruitful. Furthermore, one SNP (rs13407662) associated with small-vessel disease in the discovery phase failed genotyping in more than half of the replication cohorts. Genotyping multiple SNPs at this locus might have avoided this issue. We also cannot rule out confounding because of other environmental factors or phenotypic heterogeneity. Although phenotyping was done using the TOAST classifi cation system, inter pretation of exact classifi cation criteria and defi nitions can diff er across countries and studies, which becomes more of an issue when there are many smaller cohorts, such as in the replication phase of this study. Varying cohort study designs might also increase heterogeneity in large-scale meta-analyses.
Our results show that although genetic variants can be detected with ischaemic stroke, all associations we were able to confi rm were specifi c to a stroke subtype. This fi nding has two implications. First, to maximise success of genetic studies in ischaemic stroke, detailed stroke subtyping is needed. Second, it implies that diff erent pathophysiological mechanisms are associated with diff erent stroke subtypes and, therefore, drug treatments might have diff erent eff ects in diff erent stroke subtypes. Most trials of secondary prevention in stroke have included all strokes, with limited stroke subtyping, and further studies with the detailed sub typing would be required to show diff erent pharma cological profi les.
METASTROKE brings together GWAS data from most groups working in the area of stroke genetics worldwide. This paper describes the details of every population and represents the fi rst analysis of the datasets. Various additional GWAS studies in stroke are currently taking place or have recently been completed, including a recently published GWAS in an Australian population, which confi rmed an association at a 6p21.1 locus with large-artery atherosclerotic stroke. 31 The addition of these data might lead to identifi cation of further novel associations with ischaemic stroke.
Panel: Research in context
Systematic review
As part of the International Stroke Genetics Consortium we had access to several genome-wide association datasets for ischaemic stroke, including both published and unpublished studies. To identify other studies, we searched PubMed on July 30, 2012, for published genome-wide association studies in ischaemic stroke with the terms "ischaemic stroke" and "genome wide association". The search returned studies already included by the consortium members. No further studies with ischaemic stroke as a primary endpoint were identifi ed.
Interpretation
This is the largest analysis of genetic data for ischaemic stroke. This study provides evidence that common genetic variation has a role in the pathogenesis of ischaemic stroke. The genetic associations identifi ed so far are with specifi c stroke subtypes, suggesting that the diff erent subtypes of ischaemic stroke have diff erent risk factor profi les and pathophysiological mechanisms, with potential implications for all areas of stroke research. 
